Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase A...
December 21 2020 - 4:30PM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy
company committed to cures for blood cancers and serious
hematologic diseases, today announced that its previously announced
public offering closed on December 21, 2020. The total number of
ordinary shares sold by the Company in the offering was 9,343,750,
inclusive of the full exercise of the underwriters’ option to
purchase up to an additional 1,218,750 shares, at the public
offering price of $8.00 per share, less underwriting discounts and
commissions. After giving effect to the option closing, the shares
sold by the Company resulted in aggregate gross proceeds to the
Company of $74.75 million before deducting underwriting discounts
and commissions and estimated offering expenses payable by the
Company.
Piper Sandler & Co., Evercore Group L.L.C. and JMP
Securities LLC acted as joint book-running managers for this
offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission on Form F-3 (File
No. 333-234701) and declared effective on November 27, 2019. This
offering was made by means of a prospectus supplement, which along
with the accompanying base prospectus are part of the effective
registration statement. Copies of the final prospectus supplement
and the accompanying prospectus related to this offering may be
obtained from: Piper Sandler & Co., 800 Nicollet Mall, J12S03,
Minneapolis, Minnesota 55402, Attention: Prospectus Department, by
telephone at (800) 747-3924 or by email at prospectus@psc.com;
Evercore Group L.L.C., 55 East 52nd Street, New York, New York
10055, Attention: Equity Capital Markets, by telephone: (888)
474-0200, or by email at ecm.prospectus@evercore.com; or JMP
Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco,
CA 94111, Attention: Prospectus Department, by calling (415)
835-8985 or by email at syndicate@jmpsecurities.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Gamida Cell Gamida Cell is an advanced cell therapy
company committed to cures for blood cancers and serious blood
diseases. We harness our cell expansion platform to create
therapies with the potential to redefine standards of care in areas
of serious medical need.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201221005718/en/
Investor Contact: Stephanie Ascher Stern Investor
Relations, Inc. stephanie.ascher@sternir.com
1-212-362-1200
Media Inquiries: Matthew Corcoran
mcorcoran@tenbridgecommunications.com 1-617-866-7350
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024